Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
Phase 2
Terminated
NCT05584202
| Condition | SARS-CoV-2 |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | ModernaTX, Inc. |
|---|
| Status | Terminated |
|---|
| Enrollment | 68 participants |
|---|
| Interventions | mRNA-1273.214 |
|---|
| Start date | Sep 30, 2022 |
|---|
| Completion date | Nov 15, 2024 |
|---|
| Results posted | Nov 26, 2025 |
|---|
Summary
The study evaluated the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to \< 6 months.
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First Injection
Day 1 up to 7 days after first vaccination (up to Day 8) · Participants
| mRNA-1273.214 5 μg First Injection (Solicited Safety Set) | 23 Participants |
|---|
| mRNA-1273.214 10 μg First Injection (Solicited Safety Set) | 7 Participants |
|---|
| mRNA-1273.214 5 μg First Injection (Solicited Safety Set) | 8 Participants |
|---|
| mRNA-1273.214 10 μg First Injection (Solicited Safety Set) | 3 Participants |
|---|
| mRNA-1273.214 5 μg First Injection (Solicited Safety Set) | 1 Participants |
|---|
| mRNA-1273.214 10 μg First Injection (Solicited Safety Set) | 0 Participants |
|---|
Number of Participants With Solicited Local and Systemic ARs After Second Injection
Day 57 up to 7 days after second vaccination (up to Day 64) · Participants
| mRNA-1273.214 5 μg Second Injection (Solicited Safety Set) | 18 Participants |
|---|
| mRNA-1273.214 10 μg Second Injection (Solicited Safety Set) | 6 Participants |
|---|
| mRNA-1273.214 5 μg Second Injection (Solicited Safety Set) | 7 Participants |
|---|
| mRNA-1273.214 10 μg Second Injection (Solicited Safety Set) | 2 Participants |
|---|
| mRNA-1273.214 5 μg Second Injection (Solicited Safety Set) | 1 Participants |
|---|
| mRNA-1273.214 10 μg Second Injection (Solicited Safety Set) | 0 Participants |
|---|
Number of Participants With Unsolicited Adverse Events (AEs) After Any Injection
Day 1 up to 28 days after any vaccination (up to Day 85) · Participants
| mRNA-1273.214 5 μg (Safety Set) | 24 Participants |
|---|
| mRNA-1273.214 10 μg (Safety Set) | 8 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.